PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12137402

AZD-2563 AstraZeneca.

Alan P Johnson
View original source ↗Export metadata ↓

Abstract

AstraZeneca is developing AZD-2563, an oxazolidinone with a novel mechanism of action, for the potential treatment of gram-positive bacterial infections, including those caused by multidrug-resistant strains [349551], [399542]. As of December 2001, AZD-2563 had completed an escalating-dose phase I trial in the UK and was being developed in the US [433897]; at this time, AstraZeneca did not expect launch until after 2004 [431673]. In October 2001, Morgan Stanley estimated launch in 2004 with sales of US $20 million in that year, rising to US $46 million in following years [429700].

Explore related subjects

AcetamidesAnimalsAnti-Bacterial AgentsDisease Models, AnimalGram-Positive BacteriaGram-Positive Bacterial InfectionsLinezolidMicrobial Sensitivity TestsOxazolidinonesStructure-Activity RelationshipJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Alan P Johnson. 2002. AZD-2563 AstraZeneca.. https://pubmed.ncbi.nlm.nih.gov/12137402/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists.

A series of biphenylaminocyclopropane carboxamide based bradykinin B1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.

Acetamides↗
PubMed2007

Spontaneous enzymatically mediated dynamic kinetic resolution of 8-amino-5,6,7,8-tetrahydroquinoline.

A spontaneous dynamic kinetic resolution of 8-amino-5,6,7,8-tetrahydroquinoline 1 was observed in the presence of Candida antarctica Lipase B, in which a >60% yield of (R)-acetamide [(R)-2] was isolated from the racemic amine. The spontaneous formation of ketone 3, followed by a condensation/hydrolysis sequence with the remaining (S)-amine 1, via enamine 4, provides the necessary racemization pathway.

Acetamides↗
PubMed2007

Total synthesis of bistramide A.

An asymmetric synthesis of the marine metabolite bistramide A is reported. The synthesis relies on the utility of three different organosilane reagents to construct all principle fragments and 8 of the 11 stereogenic centers of the natural product. [structure: see text].

Acetamides↗